Pridgen
Christopher Pridgen, Weehawken, NJ US
Patent application number | Description | Published |
---|---|---|
20140044759 | DRUG SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARING THE SAME - Drug substances, which comprise a solid amorphous forms of a compound of structural formula I and have a BET specific surface area of up to about 94 m | 02-13-2014 |
Christopher Stanley Pridgen, Union City, NJ US
Patent application number | Description | Published |
---|---|---|
20080254128 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 10-16-2008 |
20100324295 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates a process for the preparation of a compound of the formula: | 12-23-2010 |
Christopher Stanley Pridgen, Weehawken, NJ US
Patent application number | Description | Published |
---|---|---|
20120294935 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 11-22-2012 |
Eric Pridgen, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20100303723 | DRUG DELIVERY SYSTEMS USING FC FRAGMENTS - The present invention provides drug delivery systems comprising FcRn binding partners (e.g., FcRn binding partner, Fc fragment) associated with a particle or an agent to be delivered. Inventive drug delivery systems allow for binding to the FcRn receptor and transcytosis into and/or through a cell or cell layer. Inventive systems are useful for delivering therapeutic agents across the endothelium of blood vessels or the epithelium of an organ. | 12-02-2010 |
Eric M. Pridgen, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20150265716 | Nanoparticles For Targeted Delivery of Multiple Therapeutic Agents and Methods of Use - Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles. | 09-24-2015 |
Jeremy C. Pridgen, Cary, NC US
Patent application number | Description | Published |
---|---|---|
20110097713 | Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 - Compositions and methods for determining an optimal dose of a medication for a subject are described that include determining the subject's genotype for the CYP2C9 and VKORC1 genes and determining the dose of the medication based on the genotype. Articles of manufacture also are provided that include polynucleotides for genotyping. | 04-28-2011 |